The Center for Biosimilars recaps the top 5 biosimilars articles for the week of January 1, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of January 1.
Number 5: Many pharma companies rang in the new year with increases to their drugs’ list prices.
Number 4: The FDA has released new draft guidance for industry on good practices for submitting abbreviated new drug applications to speed generic drug approvals.
Number 3: New data show that LG Chem’s proposed biosimilar etanercept matches the reference Enbrel in terms of safety and efficacy.
Number 2: Drug maker Protalix announced positive phase 2 clinical data for an orally administered anti-TNF therapy.
Number 1: Momenta and Mylan have announced that they will begin clinical trials of M710, a proposed biosimilar to Eylea.
Finally, this week, contributor Brian Lehman explains why the so-called Medicare Part D “donut hole” creates an unintentional barrier to biosimilars in the United States. Read Lehman’s article and more content from expert contributors at centerforbiosimilars.com.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.